Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Ipsen
  6. Summary
    IPN   FR0010259150

IPSEN

(IPN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/17/2021 06/18/2021 06/21/2021 06/22/2021 06/23/2021 Date
90.3(c) 89.2(c) 88.3(c) 90.26(c) 90.4(c) Last
200 750 351 080 106 032 110 642 133 463 Volume
-0.40% -1.22% -1.01% +2.22% +0.16% Change
More quotes
Estimated financial data (e)
Sales 2021 2 737 M 3 264 M 3 264 M
Net income 2021 542 M 646 M 646 M
Net Debt 2021 83,7 M 99,9 M 99,9 M
P/E ratio 2021 13,8x
Yield 2021 1,13%
Sales 2022 2 762 M 3 294 M 3 294 M
Net income 2022 532 M 634 M 634 M
Net cash position 2022 232 M 276 M 276 M
P/E ratio 2022 14,0x
Yield 2022 1,15%
Capitalization 7 477 M 8 931 M 8 916 M
EV / Sales 2021 2,76x
EV / Sales 2022 2,62x
Nbr of Employees 5 703
Free-Float 41,9%
More Financials
Company
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes... 
Sector
Pharmaceuticals
Calendar
07/29Earnings Release
More about the company
Ratings of Ipsen
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about IPSEN
06/18IPSEN  : A year-long partnership with the ISPC
PU
06/17IPSEN  : launches Perspectives Matter around World Kidney Cance...
PU
06/14ISPRM 2021 : New Ipsen analysis highlights potential treatment gap in adults liv..
AQ
06/11IPSEN  : Finds Potential Treatment Gap Among Spasticity Patients in US
MT
06/11IPSEN  : ISPMR 2021 – 11 June 2021.pdf
PU
06/07IPSEN  : Exelixis Say Phase 3 Trial of Cabozantinib Drug in Differentiated Thyro..
MT
06/07IPSEN  : Exelixis COSMIC-311 ASCO – 7 June 2021.pdf
PU
06/05IPSEN  : World Environment Day 2021
PU
05/31TODAY'S ANALYST RECOMMENDATIONS : Advanced Micro Devices, AstraZeneca, Bodycote,..
05/31IPSEN  : US FDA Accepts Ipsen's Approval Request For Ultra-Rare Genetic Disorder..
MT
05/31IPSEN : Ex-dividend day for final dividend
FA
05/28IPSEN  : Palovarotene FDA acceptance – 28 May 2021.pdf
PU
05/28IPSEN  : Information relating to compensation elements of ALC – 28 mai 202..
PU
05/28IPSEN  : Compensation policy for corporate officers, result of vote SM – 2..
PU
05/28IPSEN  : Information relating to compensation elements of DL – 28 mai 2021..
PU
More news
News in other languages on IPSEN
06/18IPSEN  : s'engage avec Gaëlle Edon dans ses défis sportifs !
06/18IPSEN S A  : Rediffusion AG – VF 2021.pdf
06/17IPSEN  : lance la campagne Perspectives Matter à l'occasion de ...
06/11Les valeurs à suivre aujourd'hui à la Bourse de Paris Vendredi 11 juin 2021
06/11IPSEN  : ISPMR 2021 – 11 Juin 2021.pdf
More news
Analyst Recommendations on IPSEN
More recommendations
Stock Trading Strategies
IPSEN - 03/31
Helped by a technical support level
BUY
More Stock Trading Analysis
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | IPN | FR0010259150 | MarketScreener
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 90,40 €
Average target price 91,03 €
Spread / Average Target 0,70%
EPS Revisions
Managers and Directors
NameTitle
David G. Loew Chief Executive Officer & Director
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Marc M. P. de Garidel Non-Executive Chairman
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN32.93%8 888
JOHNSON & JOHNSON3.96%430 876
ROCHE HOLDING AG11.75%324 905
PFIZER, INC.7.61%221 725
NOVARTIS AG2.56%209 282
ABBVIE INC.7.05%202 586